Comparative Pharmacology
Head-to-head clinical analysis: HEDULIN versus HEPARIN SODIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEDULIN versus HEPARIN SODIUM IN PLASTIC CONTAINER.
HEDULIN vs HEPARIN SODIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEDULIN (phenindione) is an anticoagulant that inhibits vitamin K-dependent synthesis of coagulation factors II, VII, IX, and X in the liver, thereby reducing thrombus formation.
Heparin binds to antithrombin III, inducing conformational change that accelerates its inhibition of thrombin (factor IIa), factor Xa, and other coagulation factors (IXa, XIa, XIIa).
Oral, 200-400 mg initially, then 100-200 mg every 6-12 hours; maximum daily dose 1200 mg.
Initial IV bolus of 80 units/kg followed by continuous IV infusion of 18 units/kg/hour; dose adjusted based on aPTT. Typical infusion range 10-30 units/kg/hour. Subcutaneous route: 5000 units every 8-12 hours for prophylaxis.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in patients with normal renal function; may be prolonged to 30-40 hours in renal impairment, necessitating dose adjustment.
30-150 minutes (dose-dependent: 0.5-1.5 h at low doses, up to 2.5 h at high doses). Prolonged in hepatic or renal impairment.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; the remainder is metabolized hepatically and excreted in feces via bile.
Renal (predominantly), with minor biliary/fecal elimination. Clearance is dose- and concentration-dependent due to saturable binding.
Category C
Category A/B
Anticoagulant
Anticoagulant